Tarsus Pharmaceuticals provides 2025 update

The company states: “Tarsus Pharmaceuticals (TARS) provided an update on the Company’s key priorities for 2025, including plans to advance TP-04 for the potential treatment of Ocular Rosacea, another category-creating opportunity in eye care. Based on FDA feedback, the Company has established a clear regulatory path forward for TP-04 and plans to initiate a Phase 2 study in the second half of 2025. Results are anticipated in 2026.” Tarsus also notes that it is “On-track for potential European regulatory approval of a preservative-free formulation of XDEMVY in 2027.” “2024 was a groundbreaking year for Tarsus as we established XDEMVY as one of the most successful eye care launches to date. With consistent quarter-over-quarter revenue growth, rapid physician adoption, broad payer coverage to date, and continued acceleration in the number of bottles delivered to patients in the fourth quarter of 2024, our path to eye care leadership is clear,” said Bobak Azamian, CEO. “I expect 2025 to be even more transformational as we turn up the dial on key strategic launch initiatives, plan to generate more new evidence highlighting the impact of XDEMVY and our pipeline candidates, and pursue Ocular Rosacea as the next potentially revolutionary opportunity in eye care.”